Antisoma/Novartis halt Phase III NSCLC trial on lack of efficacy
This article was originally published in Scrip
Executive Summary
Antisoma and Novartis are halting the Phase III ATTRACT-1 trial of ASA404 after an interim result analysis showed the drug has little or no prospect of improving survival in patients with newly diagnosed non-small cell lung cancer (NSCLC).